If you have prostate cancer that has spread, your healthcare provider may prescribe Xtandi. This drug is specifically designed to treat prostate cancer that has returned or progressed despite other treatments. It comes as a capsule that is taken once daily. Back pain, diarrhea, and weakness are some of the possible side effects.
What Is Xtandi?
Xtandi® (enzalutamide) is a prescription medication approved to treat castration-resistant prostate cancer that has spread to other parts of the body. Castration-resistant prostate cancer is prostate cancer that has returned or progressed despite medical or surgical treatments to lower testosterone levels. Xtandi is approved for use in men who have previously been treated with a chemotherapy medicine known as docetaxel (Docefrez™, Taxotere®).
Xtandi is made by Catalent Pharma Solutions, LLC, for Astellas Pharma US, Inc., and Medivation, Inc.
How Does Xtandi Work?
Androgens (male sex hormones, such as testosterone) stimulate the growth of prostate cancer. Xtandi is known as an androgen receptor inhibitor (also known as an antiandrogen). It works by binding to androgen receptors and preventing testosterone from also binding to the receptor. Xtandi is also thought to block the downstream effects of testosterone after it binds to the androgen receptor.
Clinical Effects of Xtandi
In a clinical study, Xtandi extended the life of men with prostate cancer that had spread beyond the prostate and was resistant to treatment to lower testosterone levels.
In this study, men given Xtandi lived a median of 18.4 months after starting treatment. The median is the midpoint, meaning half of the men lived longer than 18.4 months and half did not live for 18.4 months. Men who were given a placebo pill (a sugar pill that does not contain any active ingredients) lived a median of 13.6 months.
All the men in the study had previously been treated with docetaxel.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed September 28, 2012.
Enzalutamide. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2011. Available from Wolters Kluwer Health, Inc. Accessed September 28, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click